Bli medlem
Bli medlem

Du är här


Vitrolife AB (publ): Conference call interim report

Invitation to attend Vitrolife's conference call regarding
presentation of the interim report for the period January - June
2014. The presentation will be held in English.

Time: Friday, July 11, 2014 at 10 a.m. CET.

Registration can preferably be done in advance under the following

or shortly before the conference starts on:

· Sweden dial in number: +46 (0)8 5052 0110
· UK dial in number: +44 (0)20 7162 0077

Conference name: Vitrolife, conference ID: 946172

Vitrolife participants:

Thomas Axelsson, CEO
Mikael Engblom, CFO

The press release for Vitrolife's interim report will be released at
08.30 a.m. CET on Friday, July 11, 2014.

Before the conference call, slides will be available at the company
web page,

A recorded version of the conference call will be available for seven
days on number

+46 (0)8 5052 0333 (Sweden) or +44 (0)20 7031 4064 (UK), access code

Gothenburg, July 2, 2014

For further information, please contact:
Mikael Engblom, CFO, 46 31 721 80 14

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.


Vitrolife ( is an international
medical device Group. Vitrolife Fertility
( product area develops,
produces and markets medical devices for assisted reproduction. Work
is also carried out to enable the use and handling of stem cells for
therapeutic purposes

Vitrolife ( has approximately
240 employees and the company's products are sold in almost 110
markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United
Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share
( is
listed on NASDAQ OMX Stockholm
Small Cap.


Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate
identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80
99. E-mail: Website:


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.